Navigation Links
Resverlogix Completes Dosing for ASSERT Trial
Date:5/12/2010

Completion occurs 5 months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, May 12 /PRNewswire-FirstCall/ - Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug. Our clinical team and our collaborators at the Cleveland Clinic will now spend the next few months assessing the study results to best plan for upcoming trials. The swift completion of the ASSERT study further allows us to make better assessments in identifying optimal dosing regimens moving forward," explained Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey continued, "Earlier studies have indicated that the drug worked best in those subjects with low HDL, therefore we will further assess if RVX-208 has a targeted effect in this high risk cardiovascular disease population. The rapid enrollment and dosing success for this trial was in large part due to having one organized Internal Review Board (IRB) for all 40 sites involved in the trial."

The ASSERT trial is a randomized, double-blind, placebo-controlled, multi-centered US study for 13 weeks of administration of RVX-208, which has enrolled 299 patients with stable coronary artery disease for a period of 13 weeks. The primary endpoint of the study is to determine if RVX-208 will produce an increase in plasma Apolipoprotein A-I (ApoA-I) levels compared to placebo group after three months of dosing. Other objectives are to examine the safety and tolerability of RVX-208 and to com
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Aoxing Pharmaceutical,Company, Inc. (OTC Bulletin Board: CAXG), which ... highly regulated narcotic,medicines and pain medication in China, ... fiscal 2008 ended September 30, 2007. China ... first quarter of fiscal 2008, a 33% sequential ...
... Convergence and New Opportunities, NEW BRUNSWICK, N.J., Nov. ... organizational changes to sharpen its,focus on opportunities outside its ... health care. These include the creation of a new,strategy ... The,changes are designed to accelerate growth for Johnson & ...
... 14 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... development and commercialization of novel drugs in the,therapeutic ... its financial results for the third quarter ended ... The net loss for the three months ended ...
Cached Biology Technology:China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 2China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 3China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 4China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 5Johnson & Johnson Announces Changes to Accelerate Growth 2Johnson & Johnson Announces Changes to Accelerate Growth 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9
(Date:4/18/2014)... Peru found that 28 percent of the batches ... Many pills released the active ingredient too slowly. ... had no active ingredient at all. , ... Georgia Institute of Technology developed a sophisticated approach ... drugs and then characterize their chemical composition. The ...
(Date:4/18/2014)... URBANA, Ill. For the past 20 years, researchers ... of the research findings have suggested that soil organic ... or conventional tillage systems to no-till systems. However, there ... no-till systems in corn and soybean rotations without cover ... soil organic carbon stocks at the published rates. , ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... Cincinnati, OH, April 14, 2011 -- The number of couples ... often use assisted reproductive technologies, like in vitro fertilization (IVF), ... can also increase the risk of multiple pregnancies (i.e., twins ... one embryo. Twins and triplets are likely to be ...
... hormone known to inhibit aging can also protect kidneys against ... Scientists led by Dr. Makoto Kuro-o, associate professor of pathology, ... renal fibrosis a common complication of chronic kidney disease ... online in the Journal of Biological Chemistry . ...
... and economic security concerns have triggered interest in using algae-derived ... or any other biofuel source can require a ... smart about where we grow algae can drastically reduce how ... biofuel, while being water-wise, could also help meet congressionally mandated ...
Cached Biology News:New study finds stronger regulations of in vitro fertilization may save lives 2Anti-aging hormone Klotho inhibits renal fibrosis, cancer growth 2Study: Algae could replace 17 percent of US oil imports 2Study: Algae could replace 17 percent of US oil imports 3Study: Algae could replace 17 percent of US oil imports 4
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Signets Xylene Resistant (X/R) Red System ... X/R Red Activator and X/R Red ... with alkaline phosphatase to produce red ... ,Kit Contains:, , Buffer, 100 ...
Human Cell Line Slides...
Biology Products: